Fluoroquinolones - A current review;Fluorchinolone - Eine aktuelle übersicht

Medizinische Monatsschrift fur Pharmazeuten

Volumn 24, Issue 7, 2001, Pages 215-225

  Christ, W ^a   Kemmler, H ^a  

^a NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINAFLOXACIN; ENOXACIN; ENOXOR; FLEROXACIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SITAFLOXACIN; SPARFLOXACIN; TROVAFLOXACIN; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

BACTERIAL INFECTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; GASTROINTESTINAL INFECTION; HUMAN; LIVER TOXICITY; NEUROTOXICITY; PHOTOTOXICITY; REVIEW; TREATMENT INDICATION; ANTIBIOTIC RESISTANCE; BACTERIUM; DRUG EFFECT; GENETICS; MICROBIOLOGICAL EXAMINATION;

ANTI-INFECTIVE AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 0035404770     PISSN: 03429601     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. The future of the quinolones
2. Quinolone activity against anaerobes
3. Moxifloxacin
4. The role of fluoroquinolones in tuberculosis therapy
5. Pefloxacin clinical pharmacokinetics
6. Association of alterations in Par C and Gyr A proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones
7. Quinolone arthropathy in animals versus children
8. The photomutagenicity of fluoroquinolones in tests for gene mutation, chromosomal aberration, gene conversion and DNA breakage (comet assay)
9. Central nervous system toxicity of quinolones: Human and animal findings
10. Adverse reactions to fluoroquinolones in adults and children
11. Verträglichkeit und anwendungssicherheit von fluorchinolonen. Spezifische toxikologische aspekte und nebenwirkungen
12. Toxicity of the quinolones
13. Safety of ciprofloxacin in children: World-wide clinical experience based on compassionate use. Emphasis on joint evaluation
14. Fleroxacin: A review of its chemistry, microbiology, toxicology, pharmacokinetics, clinical efficacy and safety
15. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy
16. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability
17. Structure-activity and structure-side-effect relationships for the quinolone antibacterials
18. Transfer kinetics of pefloxacin into cerebrospinal fluid after one hour i. v. infusion of 400 mg in man
19. Refining the fluoroquinolones
20. Clinafloxacin antibacterial activity
21. Activity of newer fluoroquinolones in vitro against Gram-positive bacteria
22. Drug efflux and par C mutations are involved in fluoroquinolone resistance in viridans group streptococci
23. Norfloxacin, the first of a new class of fluoroquinolone antimicrobials, revisited
24. Nalidixic acid resistance: A second genetic character involved in DNA gyrase activity
25. Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections
26. Mechanism of action of nalidixic acid on Eschericha coli II. Inhibition of deoxyribonucleic acid synthesis
27. Trovafloxacin
28. Mode of action of fluoroquinolones
29. Induktion des MAR-Phänotyps als mögliche ursache für die entwicklung der fluorchinolon-resistenz bei E. coli
30. Fluoroquinolones in paediatrics
31. In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans Streptococci and genomic organization of the parE-parC region in S. mitis
32. The absolute oral bioavailability of sparfloxacin in healthy male subjects
33. + channel HERG
34. Characterization of fluoroquinolone-induced Achilles tendon toxicity in rats: Comparison of toxicities of 10 fluoroquinolones and effects of anti-inflammatory compounds
35. Sparfloxacin selects gyrase mutations in first-step Mycoplasma hominis mutants, whereas ofloxacin selects topoisomerase IV mutations
36. Fluoroquinolones enhance UVA-induced skin tumors
37. Accidental overdose of intravenous ofloxacin with benign outcome
38. Prävalenz der antibiotikaresistenz bei klinisch wichtigen infektionserregern in mitteleuropa
39. Resistenzsituation bei klinisch wichtigen infektionserregern gegenüber chemotherapeutika in mitteleuropa
40. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract
41. c prolongation with d,I-Sotalol in women versus men
42. Fluoroquinolone toxicity profiles: A review focusing on newer agents
43. Safety profile of sparfloxacin (SPAR) in North American Phase III clinical trials
44. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs
45. Multiple novel inhibitors of the Nor A multidrug transporter of Staphylococcus aureus
46. Mode of Action
47. Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800 mg
48. Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses
49. Einteilung der fluorchinolone (PEG-Empfehlungen)
50. Quinolones in the aged
51. Penetration of lipophilic agents with multiple protonation sites into bacterial cells. Tetracyclines and fluoroquinolones as examples
52. Clinical features and management of adverse effects of quinolones antibacterials
53. Gatifloxacin
54. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials
55. Pharmacokinetics of oral and intravenous clinafloxacin
56. Pefloxacin diffusion into serum and CSF in men with and without meningitis
57. Lack of quinolone-induced arthropathy in children
58. Increasing resistance of enterococci to ciprofloxacin
59. World-wide clinical data on efficacy and safety of ciprofloxacin
60. Ultrastructure of Achilles tendons of rats treated with ofloxacin and fed a normal or magnesium-deficient diet
61. Clinical pharmacokinetics of sparfloxacin
62. Pharmakokinetik und pharmakodynamik von levofloxacin
63. Phototoxizität, neurotoxizität und chondrotoxizität der chinolone: Experimentelle daten und klinische erfahrungen
64. Nebenwirkungen der neueren fluorchinolone
65. Toxicity of quinolones
66. Metabolism and excretion of moxifloxacin
67. Basic pharmacokinetics of moxifloxacin
68. Toxicity of the quinolone antimicrobial agents
69. Klinische relevanz der auswirkungen von sparfloxacin auf den herzrhythmus
70. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy
71. Pharmacokinetics and pharmacodynamics of fluoroquinolones
72. Toxicology and safety pharmacology of quinolones
73. Quinolone antibacterials. An update of their pharmacology and therapeutic use
74. Effects of magnesium deficiency on magnesium and calcium content in bone and cartilage in developing rats in correlation to chondrotoxicity
75. Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use
76. Grepafloxacin
77. Bakterielle resistenz gegenüber chinolonen (ciprofloxacin)
78. A review of the clinical pharmacology of moxifloxacin, a new 8-methoxyquinolone, and its potential relation to therapeutic efficacy
79. Penetration of pefloxacin into cerebrospinal fluid of patients with meningitis